Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
Conference Coverage
Global effort needed to widen access to HSCT
Publish date:
December 10, 2022
FROM ASH 2022
A version of this article first appeared on
Medscape.com
.
Pages
« first
1
2
Recommended Reading
Fourth patient cleared of HIV after stem cell transplant for blood cancer
MDedge Hematology and Oncology
AML’s seasonal peak suggests viral or environmental etiology
MDedge Hematology and Oncology
First drug therapy approved for childhood GVHD
MDedge Hematology and Oncology
Bias and other barriers to HSCT access
MDedge Hematology and Oncology
Pivotal trials in blood cancers don’t mirror patient populations
MDedge Hematology and Oncology
`Wonder Woman’ launches myelofibrosis research foundation
MDedge Hematology and Oncology
Drug combo holds promise of better AML outcomes
MDedge Hematology and Oncology
Worldwide trial seeks to revolutionize pediatric leukemia care
MDedge Hematology and Oncology
FDA approves olutasidenib for some AML patients
MDedge Hematology and Oncology
ASH 2022: New clinical data challenge long-held assumptions
MDedge Hematology and Oncology
AML
Transplant
All Specialties
